Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of FX-322 in Age-Related Sensorineural Hearing Loss
NCT04601909Phase 1Completed
- Sponsor
- Frequency Therapeutics
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in presbycusis comparing FX-322 with Placebo (2 arms). Primary endpoints: Number of patients with treatment-related adverse events at 3 months, Number of patients with abnormal changes from baseline in otoscopic examinations at 3 months and 2 more. Started Sep 2020; status: completed.
02
Drugs
FX-322
03
Conditions
presbycusis
Beyond the preview
Go deeper on NCT04601909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601909.